KOSPIHolding Companies006120

SK Discovery

₩68,100▲ 2.25%2026-11-18 close
Market Cap
₩1.2T
Turnover
₩1.7B
Volume
20K
Shares out.
17.4M
PER
3.4×
PBR
0.4×
EPS
₩21,122
Dividend Yield
2.76%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩2,000 per share · Prices as of the 2026-11-18 close

01

Report overview

Holding Earnings: Operating Recovery vs. Non-Operating Gains

Pre-tax profit rose 311% in Q3 2026, but most of the gain came from non-operating items, so subsidiary recovery and earnings quality need to be read together.

  1. 1

    Q3 2026 revenue was KRW 3.44 trillion, up 32.3% year on year, and the largest quarterly top line since the holding company was formed in December 2017.

  2. 2

    Operating profit was KRW 170.8 billion, up only 1.6%, while the operating margin slipped to 5.0% from 6.5%.

  3. 3

    About 99% of the pre-tax profit increase came from improvement in non-operating items.

  4. 4

    The company raised KRW 1.6 trillion by selling minority stakes in power subsidiaries, and cash and cash equivalents stood at KRW 3.85 trillion at the end of Q3 2026.

  5. 5

    Q2 2026 posted an operating loss of KRW 30.4 billion and a net loss attributable to controlling shareholders of KRW 46.8 billion, so quarterly swings remain wide.

02

Business structure

SK Discovery was converted into an investment-focused holding company when it split its business units in December 2017, and it operates by holding and controlling subsidiary stakes.

Its main subsidiaries are SK Gas, which handles LNG and LPG; SK Chemicals, which covers eco-friendly materials and pharmaceuticals; SK bioscience, which runs the vaccine business; and SK Plasma, a blood products company. The group's core businesses are summarized as chemicals, bio and energy.

SK Chemicals operates eco-friendly materials (Green Chemicals) and pharmaceuticals and bio (Life Science), along with other businesses including energy. Vaccines sit with SK bioscience, which according to 2021 reports has handled contract manufacturing of COVID-19 vaccines for AstraZeneca.

SK Gas is diversifying its revenue sources by adding LNG and power generation to its LPG business. In Q3 2026, SK Gas's pre-tax profit rose 86% to KRW 285.8 billion, lifting consolidated results. By contrast, SK Chemicals' standalone operating profit fell 45% to KRW 16.4 billion.

The largest shareholder is Vice Chairman Choi Chang-won, and the company has been described as an independent business group with no ownership ties to the SK group's controlling family. Its mix of gas, chemical and bio subsidiaries differs from that of peers in the same holding-company sector, such as SK Square.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.6T₩168.1B6.5%
2025Q4₩2.7T-₩5.5B−0.2%
2026Q1₩3.3T₩189.8B5.8%
2026Q2₩3.1T-₩30.4B−1.0%
2026Q3₩3.4T₩170.8B5.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩8.7T₩362.2B₩427.4B4.2%15.2%97.9%
2023₩8.9T₩256.7B₩191B2.9%6.5%101.8%
2024₩9T₩172.6B₩25.2B1.9%0.9%133.6%
2025₩10.2T₩361.4B₩129.3B3.6%4.4%137.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 8.72 trillion in 2022 to KRW 10.2 trillion in 2025. Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025 with a 12.4% gain.

Operating profit fell from KRW 362.2 billion in 2022 to KRW 256.7 billion in 2023 (down 29.1%) and KRW 172.6 billion in 2024 (down 32.8%), then recovered to KRW 361.4 billion in 2025 (up 109.4%). The operating margin went 4.2%, 2.9%, 1.9% and 3.6%, bottoming in 2024 and rebounding in 2025.

Net profit attributable to controlling shareholders dropped from KRW 427.4 billion in 2022 to KRW 25.2 billion in 2024 before recovering to KRW 129.3 billion in 2025. Net income including non-controlling interests was KRW 144.6 billion in 2025, a different figure that needs to be kept separate.

The debt ratio rose from 97.9% in 2022 to 137.9% in 2025, and total liabilities at the end of 2025 were KRW 9.45 trillion. Operating cash flow was KRW 660.8 billion in 2025, up sharply from KRW 115.4 billion in 2024.

Quarterly, operating profit was KRW 168.1 billion in Q3 2025, then turned to an operating loss of KRW 5.47 billion in Q4 2025. Q1 2026 returned to operating profit of KRW 189.8 billion on revenue of KRW 3.29 trillion, up 23.7% from the prior quarter.

Q2 2026 posted an operating loss of KRW 30.4 billion, and Q3 2026 returned to operating profit of KRW 170.8 billion. Selling and administrative expenses rose by KRW 130.4 billion in Q3, offsetting most of the gross profit gain.

Q3 2026 net profit attributable to controlling shareholders of KRW 207.7 billion was up 1,505.0% year on year, but the swing in non-operating items was the main driver. Of Q3 2026 net income of KRW 334.6 billion, KRW 126.9 billion belonged to non-controlling interests.

The company attributed the results to subsidiary improvements and gains from portfolio restructuring. The four-quarter sum of net profit attributable to controlling shareholders is KRW 382.3 billion.

05

Industry analysis

SK Discovery's earnings depend heavily on the conditions of its subsidiaries. SK Gas improved results by exploiting the price gap between LNG and LPG, and whether that gain persists over several quarters will show up in quarterly results.

The chemicals side remains under pressure, with reports noting a continued burden on the chemical industry and profitability at SK Chemicals' standalone business hurt by higher raw material prices and currency swings.

The vaccine side is moving toward smaller losses, as the narrowing deficit at SK bioscience supported consolidated results at SK Chemicals. SK Plasma posted Q3 2026 operating profit of KRW 5.4 billion, helped by higher domestic and export sales and technology transfer revenue from Turkey.

On accounting, SK Chemicals was reclassified from an associate to a consolidated subsidiary in 2021, which changed how its results flow into SK Discovery's financial statements.

Compared with peers in the same sector such as SK Square, SK, LG and POSCO Holdings, SK Discovery's gas, chemical and bio subsidiaries feed into its results together.

Non-operating items include equity-method gains and financial instrument valuations, so linking subsidiary conditions to holding-company results is clearer when operating profit is used.

06

Outlook

SK Discovery plans to buy back and cancel a total of KRW 60 billion in treasury shares over three years from 2026 to 2028. It also runs a medium-term shareholder return policy that sets a minimum annual dividend per common share.

The company said it will allocate the funds raised with both financial soundness and growth in mind, and will carry out its shareholder return policy, including treasury share cancellations.

On financial capacity, the funds are seen as widening room to build competitiveness in existing businesses and explore new growth businesses. Reports say the debt ratio fell from 138% to 127%.

SK Gas plans to merge with SK Advanced to improve the efficiency of propane sourcing and PDH operations, but no merger timetable or effect has been confirmed in disclosures yet. Because the gas recovery leans on the LNG-LPG price-gap strategy, how many quarters this strategy sustains is the next key point to watch.

The chemicals burden and the vaccine loss-narrowing trend should also be tracked. The 2026 annual report and Q4 2026 results will show whether operating margin and the share of non-operating items hold up.

07

Valuation

PER
3.4×
PBR
0.4×
ROE
11.7%
EPS
₩21,122
BPS
₩204,476
Dividend per share
₩2,000

The share price currently sits well below book value per share. Because a holding company's value is tied to the book value of its subsidiary stakes, a price-to-book ratio far below 1x can be read as a discount to the value of those stakes.

For price-to-earnings, a single quarter of net profit attributable to controlling shareholders can swing sharply, so the four-quarter view is more appropriate. The four-quarter sum of net profit attributable to controlling shareholders is KRW 382.3 billion, including a net loss in Q2 2026.

Much of the Q3 2026 profit of KRW 207.7 billion came from non-operating items, so operating profit trends should be reviewed alongside any multiple. The company has a minimum dividend standard under its medium-term policy, so the dividend yield moves with the share price.

Earnings have moved from losses to profits since the 2024 low, and how much that recovery depends on subsidiaries is central to interpreting the multiples. Valuation reflects both the sustainability of earnings and the market's view of subsidiary value.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Subsidiary recovery

Operating profit returned to profit in Q1 and Q3 2026, with Q3 operating profit at KRW 170.8 billion. SK Gas's pre-tax profit rose 86% to KRW 285.8 billion on its LNG-LPG strategy. SK Plasma also posted operating profit of KRW 5.4 billion in Q3. If subsidiary gains continue, the base of holding-company earnings widens.

Expanded financial capacity

Consolidated cash and cash equivalents reached KRW 3.85 trillion at the end of Q3 2026, up KRW 1.4 trillion from year-end 2025. Sales of minority stakes in power subsidiaries raised KRW 1.6 trillion. Reports say the debt ratio fell from 138% to 127%. The extra cash widens the options for new businesses or for strengthening control over subsidiaries.

Shareholder return policy

The company plans to buy back and cancel a total of KRW 60 billion in treasury shares over 2026 to 2028. A medium-term policy also sets a minimum annual dividend per common share.

With controlling shareholders' equity at KRW 2.91 trillion at end-2025, the execution of these returns can be measured against the equity base.

09

Bear factors

Margin pressure and SG&A burden

The Q3 2026 operating margin fell from 6.5% to 5.0%. Revenue rose 32.3%, but operating profit grew only 1.6%. Selling and administrative expenses rose from KRW 243.2 billion to KRW 373.6 billion, so top-line growth did not translate into profit growth.

Quality of earnings

Most of the pre-tax profit increase came from non-operating items. Those items include financial instrument valuations and equity-method gains, so the whole increase cannot be read as asset sale gains. Such items swing quarter to quarter and may not persist. The Q2 2026 operating loss and net loss also show quarterly volatility.

Chemicals weakness and loss quarters

SK Chemicals' standalone operating profit fell 45% to KRW 16.4 billion in Q3 2026, with higher raw material prices and currency moves cited as causes. The operating losses of KRW 5.47 billion in Q4 2025 and KRW 30.4 billion in Q2 2026 show that the recovery has not been continuous.

10

Risk factors

Financial leverage

At the end of 2025, total liabilities were KRW 9.45 trillion, and controlling shareholders' equity was KRW 2.91 trillion out of total equity of KRW 6.85 trillion. The debt ratio rose from 97.9% in 2022 to 137.9% in 2025.

Asset sales have added cash, but the borrowing structure remains and may be sensitive to rates and asset values.

Non-controlling interest leakage

About 38% of consolidated net income belongs to non-controlling shareholders, so subsidiary gains do not fully match profit attributable to holding-company shareholders. Of Q3 2026 net income of KRW 334.6 billion, KRW 207.7 billion was attributable to controlling shareholders.

Subsidiary cycles and input costs

SK Gas's profits depend on the price gap between LNG and LPG, while the chemical subsidiary is exposed to raw material prices and currency moves. The sale of power subsidiary stakes is one-off in nature, so whether similar gains recur needs confirmation. A change in subsidiary conditions could magnify swings in holding-company results.

11

What to watch next

  1. End of December 2026

    Check how far the KRW 60 billion treasury share buyback and cancellation, announced as a three-year plan for 2026 to 2028, has progressed by year-end. This shows whether the shareholder return policy is being carried out.

  2. January to February 2027 (confirm the schedule in company disclosures)

    Check whether Q4 2026 preliminary operating profit stays positive or returns to a loss, which will show whether the Q1 profit and Q2 loss pattern repeats.

  3. Late March 2027 (around the annual report filing deadline)

    The 2026 annual report will show full-year operating margin, the share of non-operating items, the debt ratio and net profit attributable to controlling shareholders. These are the main points to confirm in the next periodic report.

  4. Timing to be determined (after the merger schedule is disclosed)

    Check the merger timetable of SK Gas and SK Advanced, and the effect on propane sourcing and PDH operations, through disclosures. This shows how the structural change at the gas subsidiary could affect holding-company results.

12

Overall view

SK Discovery recorded Q3 2026 revenue of KRW 3.44 trillion, the largest quarterly top line since the holding company was formed. Operating profit rose only 1.6% to KRW 170.8 billion, and the operating margin fell to 5.0%.

Most of the pre-tax profit increase came from non-operating items, so earnings quality should be read alongside the operating profit trend. SK Gas's pre-tax profit growth and the narrowing losses at the vaccine subsidiary are positive factors.

Weaker chemical profitability, higher selling and administrative costs, and the Q2 2026 loss are negative factors.

On the financial side, cash of KRW 3.85 trillion and the KRW 1.6 trillion from stake sales widen capacity, but the debt ratio of 137.9% at end-2025 and the share of non-controlling interests still need monitoring.

Shareholder returns are presented as a KRW 60 billion treasury share cancellation plan and a medium-term dividend policy. The next checkpoints are the Q4 2026 preliminary results and the operating margin and non-operating share in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. supple.kr
  2. m.news.nate.com
  3. news1.kr
  4. biz.heraldcorp.com
  5. etoday.co.kr
  6. heraldk.com
  7. supple.kr
  8. supple.kr
  9. sateconomy.co.kr
  10. bloter.net
  11. skdiscovery.com
  12. bloter.net
  13. etnews.com
  14. evolog.in
  15. bloter.net
  16. news.bizwatch.co.kr
  17. skchemicals.com
  18. hkn24.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis